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Available online 5 February 2013Abstract Embryonic stem cells (ESCs) are hypersensitive to many DNA damaging agents and can rapidly undergo cell death or
cell differentiation following exposure. Treatment of mouse ESCs (mESCs) with etoposide (ETO), a topoisomerase II poison,
followed by a recovery period resulted in massive cell death with characteristics of a programmed cell death pathway (PCD).
While cell death was both caspase- and necroptosis-independent, it was partially dependent on the activity of lysosomal
proteases. A role for autophagy in the cell death process was eliminated, suggesting that ETO induces a novel PCD pathway in
mESCs. Inhibition of p53 either as a transcription factor by pifithrin α or in its mitochondrial role by pifithrin μ significantly
reduced ESC death levels. Finally, EndoG was newly identified as a protease participating in the DNA fragmentation observed
during ETO-induced PCD. We coined the term charontosis after Charon, the ferryman of the dead in Greek mythology, to refer
to the PCD signaling events induced by ETO in mESCs.
© 2013 Elsevier B.V. All rights reserved.Introduction
Embryonic stem cells (ESCs) must maintain genomic integrity
to prevent the accumulation of mutations in the cells that will
give rise to an organism. Evidence supporting this proposition
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http://dx.doi.org/10.1016/j.scr.2013.01.010mutation frequencies are significantly suppressed compared
with mouse embryo fibroblasts (MEFs) (Cervantes et al.,
2002). Suppression of mutation may be accomplished by the
cells' capacity to rapidly repair DNA damage by constitutively
upregulating DNA repair pathways. Alternatively, cells har-
boring extensively damaged DNA can be removed from the
self-renewing stem cell population by the induction of cell
differentiation or cell death (Tichy, 2011).
When cells are stressed or when they respond to a range
of stimuli, such as damage to DNA, they can undergo cell
death, which can be characterized as programmed cell
death (PCD) or necrotic death. Necrotic death is primarily a
passive process that involves rapid ATP depletion, swelling
429ETO-induced PCD pathways in mouse ESCsand rupture of organelles and nuclei, and random DNA
breakage (Edinger and Thompson, 2004). Under certain
conditions, however, necrosis may be described as a PCD
pathway, termed necroptosis, which displays many of the
features of necrosis, but in which cell death is dependent on
the activities of the RIP1 and/or RIP3 kinases to facilitate
death (Galluzzi et al., 2011).
In addition to necroptosis, there are several other PCD
pathways known, of which the most extensively described
relies upon the activity of executioner caspases. These
proteases cleave specific target sequences in select proteins,
including Parp-1, lamins, actins, and ICAD, the inhibitor of
caspase-activated DNase (Kawahara et al., 1998). Destruction
of ICAD allows for DNA fragmentation by caspase activated
DNase (CAD), which is one of many nucleases capable of
producing DNA fragmentation during PCD.
Autophagy is typically utilized by cells to maintain energy
homeostasis, particularly during times of nutrient deprivation.
During autophagy, certain cellular components are recycled or
damaged organelles are eliminated. As a result, autophagy
can function as a pro-survival pathway, and is often activated
in response to chemotherapeutic treatments. Alternatively,
autophagy may also promote PCD in response to several types
of stimuli (Yu et al., 2004).
The level of p53 protein, which is required for PCD under
many conditions, is tightly controlled inmost cell types through
proteosome-mediated degradation. Following stress signals,
p53 can be released from the E3 ubiquitin ligases Mdm2 or
Mdm4 and becomes stabilized. It can then translocate to the
nucleus to activate target gene expression, including the
expression of genes involved in cell cycle inhibition and cell
death. Alternatively, it can migrate to the mitochondria and
promote cytochrome C release through interaction with Bcl-xL
and Bcl2 (Marchenko et al., 2000; Mihara et al., 2003).
DNA fragmentation of defined size is characteristic of many
PCD pathways and is typically dependent upon the activity of
CAD, Apoptosis-inducing factor (AIF), or Endonuclease G
(EndoG) nucleases. Under basal conditions, the inhibitor of
CAD, ICAD, binds to CAD, preventing its activity. Caspase
activation and activity degrades ICAD, which allows CAD to
cleave DNA into nucleosomal-sized fragments. AIF localizes to
the mitochondria and exhibits oxidoreductase activity (Klein
et al., 2002), however, following death signal stimulus, AIF
can be released from the mitochondria and translocate to the
nucleus to cleave DNA into large molecular weight fragments
(Joza et al., 2001; Susin et al., 1999). EndoG, like AIF, is a
mitochondrial protein which functions to generate primers for
mitochondrial DNA replication (Cote and Ruiz-Carrillo, 1993).
Similar to AIF, death signals can trigger EndoG translocation to
the nucleus to cleave DNA, however, DNA fragmentation is of
nucleosomal size (Li et al., 2001).
The current study has investigated the cell death
pathway(s) utilized by mESCs in response to etoposide
(ETO), a topoisomerase II poison that indirectly induces
DNA double strand breaks (DSBs) (Baldwin and Osheroff,
2005). The data show that ETO not only induces cell death
with hallmarks of both PCD and necrosis, but also that this
cell death is predominantly caspase- and RIP-independent.
We also demonstrate a role for lysosomal cathepsins as well
as p53 in this PCD pathway. Finally, we show that the EndoG
nuclease contributes to DNA fragmentation in ETO-induced
PCD in mESCs.Materials and methods
Cell culture and cell treatments
C57Bl/6 ESCs (designated WD44) were used for all experi-
ments unless otherwise noted and were maintained as
previously described (Tichy et al., 2011) on feeder cell layers
composed of mitomycin C-treated mouse embryo fibroblasts.
An additional C57Bl/6 ESC line, CMT1-2 was used to confirm
data obtained using WD44 ESCs. MESCs deficient for p53 were
a kind gift from J. Huang (NCI). Twenty-four hours prior to any
experiment, ESCs were separated from the feeder cells and
plated on culture dishes coated with 0.2% gelatin. Primary
mouse embryo fibroblasts (MEFs) were cultured as described
(Tichy et al., 2010) and used at passage 2 for experiments.
Cells were never allowed to become more than 70% confluent
during experimental procedures.
Additional materials and methods can be found in the
supplementary methods section and a list of pharmacolog-
ical inhibitors and their targets are listed in Supplemental
Table 2.Results
Embryonic stem cells are sensitive to ETO treatment
Embryonic stem cells of mouse (mESCs) or human (hESCs)
origin are hypersensitive to DNA damaging agents and activate
cell death or differentiation pathways to remove damaged
cells from the stem cell pool (Aladjem et al., 1998; Tichy,
2011; Van Sloun et al., 1999). To characterize the sensitivity of
mESCs to ETO, cells were treated with a low dose of drug
(10 μM) for 4 h and then harvested either immediately after
treatment (labeled 4/0), or after 2 (4/6), 20 (4/24), or 44 (4/
48) hours of recovery prior to assaying. This concentration was
chosen based on a previous report measuring DNA DSB repair
kinetics in mESCs following ETO treatment (Tichy, 2011). We
first examined the level of DNA DSBs produced by ETO
treatment and the extent of their repair as a function of
time. There was amarked increase in γH2AX foci, indicative of
DSBs, at 4 h post-treatment (Fig. 1A). During the recovery
periods, γH2AX levels significantly decreased, reflective of
DNA repair (Fig. 1A). The levels of γH2AX, however, did not
return to baseline within the timeframe of the experiment. A
consistent and substantial increase in nuclear size was also
observed 20 h post-treatment (Supplemental Fig. 1). Analysis
of the cell cycle and measurement of phosphorylated histone
H3, a marker of mitosis, revealed that treatment of mESCs
with ETO causes these cells to accumulate in the G2 phase of
the cell cycle (Fig 1B), consistent with reports for other cell
types exposed to ETO (Clifford et al., 2003; Nam et al., 2010;
Sleiman and Stewart, 2000; Smith et al., 1994).
To assess the level of cell death in ESCs treated with ETO,
bivariate flow cytometry was utilized to assess Annexin V
binding and plasma membrane permeability by vital dye
exclusion. The number of Annexin V positive cells increased
marginally after treatment with a short recovery period but
decreased at later times of recovery (Fig. 1C). There was
also a significant increase in membrane permeability 20 and
44 h post-treatment, as compared to nontreated controls.
Figure 1 ESC responses to ETO. A. ESCs were fixed immediately after 10 μM etoposide (ETO) treatment (4/0–4 hour treatment; no
recovery), or after 20 or 44 h after treatment and recovery (4/24 or 4/48), or left nontreated. Cells were stained with antibody to
γH2AX, and actin was stained with Alexa fluor 488-conjugated phalloidin. Nuclei were stained with Draq5. Cells stained with only
secondary fluorescent antibody served as a control. B. Cells were treated as indicated and analyzed for their position in the cell cycle.
To determine whether ETO induces a G2- or M-phase arrest, cells were stained with antibody to Histone H3 phospho-serine 10 (pH3
s10). Nocodazole-treated cells served as a control for mitotic arrest. C. ESCs were treated as indicated and death levels measured by
flow cytometry after staining with Annexin V and a membrane impermeable dye. Data is the result of three trials. Error bars represent
the standard error of the mean (SEM). D. DNA fragmentation assay on ESCs treated or left nontreated. DNA was isolated from all cells
(floating and attached), and electrophoresed on 2% agarose gels. Two trials are displayed. E. Western blot using whole cell protein
lysates from treated or nontreated ESCs. Expression of cleaved Parp-1 was monitored during the recovery period. Oct4 served as a
marker for the level of ESC differentiation. Actin was used as a loading control.
430 E.D. Tichy et al.Similar trends were observed with a 129/Sv strain mESC line
(Supplemental Fig. 2). Consistent with PCD signaling, DNA
isolated from ETO-treated cells revealed distinct DNA
laddering, characteristic of nucleosomal fragmentation, rath-
er than a DNA smear, indicative of necrosis. The DNA laddering
is first observed after 4 h treatment and 20 h recovery and
became more pronounced after 44 h of recovery (Fig. 1D),
consistent with increased loss of plasma membrane integrity
observed as a function of time. To confirm activation of a PCD
pathway and eliminate a role for necrosis in ETO-induced
death, Parp-1 cleavage was assessed and shown to increase
substantially post-treatment (Fig. 1E). The level of Oct4
protein remained stable after ETO treatment, indicating thatthe mESCs retained pluripotency and that ETO did not induce
them to differentiate (Fig. 1E).Caspases are not significantly activated in mESCs
after challenge with ETO
Our data show that caspase 3 is not activated in response to ETO
in C57Bl/6 and 129/Sv mESCs (Supplemental Figs. 3A and B),
confirming a previous study (Mantel et al., 2007). Under
atypical conditions, however, a small fraction of caspase 3
was cleaved following ETO treatment, as well as following
treatment of cells with UV radiation (Supplemental Fig. 3C).
431ETO-induced PCD pathways in mouse ESCsWhen the activation status of the other executioner caspases, 6
and 7, and the initiator caspases 8 and 9 were examined
following ETO treatment, there was little or no increase in
the cleavage of these caspases to indicate their activation
(Supplemental Fig. 3A). The lack of cleavage of known caspase
targets, including lamins A and C and actin (Fischer et al.,
2003), confirmed the absence of caspase activity (Supplemental
Fig. 3A). Intriguingly, expression of lamins A and C increased
after treatment, which is consistent with the observed increase
in nuclear size observed following treatment with ETO. Since
mESCs treated with ETO undergo Parp-1 cleavage, caspase
activity was further assessed. Treatment of mESCs with zVAD, a
pan caspase inhibitor, in combination with ETO showed no
reduction of Parp-1 cleavage compared with cells treated with
ETO alone, indicating that caspases are not responsible for
Parp-1 cleavage in these cells (Supplemental Fig. 3D).
Similarly, treatment of mESCs with ETO in the presence or
absence of zVAD showed no difference in the level of cell
viability based on dye exclusion, confirming that caspases do
not play a major role in ETO-induced PCD in mESCs (Supple-
mental Fig. 3E).
RIP-dependent necrosis does not significantly
contribute to ETO-induced PCD
Necroptosis is a form of PCD that is dependent on the RIP1 and/
or RIP3 kinases (Christofferson and Yuan, 2010; Declercq et al.,
2009; Galluzzi and Kroemer, 2008). We examined the
necroptotic pathway more closely following ETO treatment of
mESCs, since several features of this pathway were manifested
during the process of mESC PCD. There was nuclear swelling
following ETO treatment, a characteristic of necrotic cell
death, as well as DNA fragmentation of defined sizes and
cleavage of Parp-1, both characteristic of a PCD pathway,
suggesting that necroptosis may play a role in ETO-induced
PCD. Both RIP1 and RIP3 kinases are present in mESCs at a basal
level and increase in abundance at later time points following
exposure to ETO (Supplemental Fig. 4A), suggesting that RIP1
and RIP3 may contribute to ETO-induced PCD. To test this
proposition, the protein levels of RIP1 or RIP3 were reduced
with siRNAs (Supplemental Fig. 4B) and the extent of cell
deathwasmeasured by flow cytometry, based on exclusion of a
vital dye. Knocking down RIP3 had a significant effect on cell
death at the 4/24 time point, but this effect did not persist into
the 4/48 time point. The RIP1 knockdown had no effect on the
level of cell death at any time point (Supplemental Fig. 4C).
To independently address these findings, cells were treated
with ETO and necrostatin-1, an RIP1 kinase inhibitor, either
individually or in combination. Cells were treated with either
ETO alone or ETO in combination with necrostatin-1 for 4 h, at
which time necrostatin-1 was added back for the duration of
the recovery period. Consistent with the results using siRNA,
necrostatin-1 did not reduce the level of ETO-induced cell
death (Supplemental Fig. 4D). Thus, if necroptosis contributes
to ETO-induced mESC PCD, its role must be a minor one.
Etoposide activates pro-survival autophagy in mESCs
Autophagy has been implicated in the cell death of cervical
cancer cells following treatment with ETO (Lee et al., 2007). To
assess whether autophagy may also participate in mESC PCDafter treatment with ETO, several autophagic proteins were
assayed by Western blot. The levels of Atg5 and Beclin 1
proteins increased following treatment, as did the level of LC3β
expression and LC3β flux (Fig. 2A), suggestive of autophagy
activation. There was also a significant increase in endogenous
LC3 foci, which serves as amarker of autophagosomes, based on
Imagestream flow cytometry (Supplemental Fig. 5), further
supporting an ETO-induced autophagic process. Suppression of
Atg5, Beclin 1, or LC3β by siRNA (Fig. 2B), however, provided no
evidence for involvement of autophagy in PCD following
treatment of mESCs with ETO (Fig. 2C). Since expression of
siRNA targeted proteins was not completely eliminated, the
possibility remains that residual levels of autophagy proteins
are sufficient to induce PCD. To probe this possibility, mESCs
were treated with ETO in the presence or absence of the
autophagy inhibitors Bafilomycin A1 (BA1) and Spautin 1. The
BA1 inhibitor targets the vacuolar H+ ATPase, which is
responsible for the acidification of the lysosome, and can
prevent their fusion with autophagosomes (Yamamoto et al.,
1998). Spautin 1 inhibits two ubiquitin-specific proteases,
USP10 and USP13, both of which can prevent the ubiquitin-
mediated degradation of Beclin 1 by removal of ubiquitin groups
necessary for targeted degradation (Liu et al., 2011). Both of
these inhibitors significantly reduced the level of ETO-induced
PCD at the 24 hour time point and even more so at the 48 hour
time point (Fig. 2D). Since these data are in conflict with
findings obtained with the siRNA knockdown experiments, BA1
and Spautin 1 may target proteins and pathways other than the
vaculolar H+ ATPase and USP 10 and 13, respectively, whose
inhibition protects cells from PCD. Since LiCl2 can promote cells
to undergo autophagy by inhibiting IMPase and GSK3 (Chang et
al., 2011), mESCs were treated with ETO in the presence or
absence of LiCl2. Activating autophagy in this manner results in
more rapid degradation of LC3β-docked cargo, and can be
monitored by a reduction in LC3β protein levels. If autophagy
functions as a cell survival pathway rather than a cell death
pathway as a result of ETO challenge, then administration of
LiCl2 with ETO should reduce or show no change in the level of
cell death. Consistent with this prediction, the level of cell
death was reduced at 20 h post-treatment after stimulating
autophagy, with little or no effect on death levels by the 4/48
time point (Fig. 2E). The levels of LC3β decrease after the
mESCs are treated with LiCl2 (Fig. 2F), which reflects
degradation of LC3-docked cargo.Cathepsin involvement in ETO-induced death
Cleavage of Parp-1, a PCD metric, is mainly affected by
cathepsins and calpains, as well as caspases (Chaitanya et
al., 2010; Gobeil et al., 2001). Lysosomal proteases such as
the cathepsins are likely candidates as enzymes that cleave
Parp-1 in mESCs, since treatment with BA1 reduced PCD
levels (Fig. 2D). To test whether cathepsins and/or calpains
are involved in ETO-induced PCD, ESCs were treated with
ETO and treated concomitantly with a series of cathepsin
and calpain inhibitors. The inhibitors included zFA, an
inhibitor of cathepsins B, L, S, and H, PD150606, an inhibitor
of calpains 1 and 2, and a cathepsin G-specific inhibitor.
Treatment with zFA significantly reduced the level of cell
death at the 4/48 time point (Fig. 3A). No effect was
observed with the calpain or cathepsin G inhibitors. These
Figure 2 Autophagy is not involved in ETO-induced PCD. A. Western blots characterizing the expression patterns of proteins
involved in autophagy in mESCs prior to and after ETO treatment and recovery. Bafilomycin A1 (BA1) served as a control and inhibits
autophagy while allowing for the accumulation of autophagic intermediates. B. Western blot showing level of knockdown of Atg5,
Beclin1, or LC3β, after transient transfection of the indicated siRNAs. Cells transfected with siRNAs express GFP, which was probed
for to demonstrate equal levels of transfection compared to control vector. C. ESCs were transfected with siRNAs. Twenty four hours
posttransfection, cells were treated as indicated and flow cytometry was performed to measure plasma membrane integrity. Cells
were first sorted for GFP positive cells prior to analysis for levels of death. Error bars represent the SEM. At least 6 trials are displayed
per group. D. ESCs were treated with Spautin 1 or BA1 during ETO treatment and added back during the recovery period. Cells were
subjected to flow cytometry to measure the loss of membrane permeability. Error bars represent the SEM. F. ESCs were treated with
either NaCl or LiCl2 during and after ETO treatment and subjected to flow cytometry to analyze loss of plasma membrane integrity. F.
Western blot of ESCs treated with NaCl or LiCl2 probed for LC3. To demonstrate autophagy is increased, BA1 was added to cells for 6 h
at a concentration of 1 nM. Two exposures are provided. Actin served as a loading control. §pb0.07; *pb0.05; and #pb0.01.
432 E.D. Tichy et al.data were confirmed using zFF, a cathepsin inhibitor which
inhibits only cathepsins B and L. Again, there was a modest
but statistically significant reduction in ETO-induced PCD by
48 h (Fig. 3B), suggesting that a collaboration of several
cathepsins is involved in ETO-induced PCD in mESCs.
Since none of the broad cathepsin inhibitors completely
protected the mESCs from cell death, in order to identify which
cathepsins are induced following ETO treatment that may also
play a role in PCD, quantitative RT-PCR was used to probe the
levels of all known murine cathepsin mRNAs in unchallenged
MEFs and ESCs, and from ESCs treated with ETO and allowed to
recover. A majority of the cathepsin genes were expressed in
both cell types at varying levels; with some exceptions, the
levels were generally higher in MEFs than in ESCs (Fig. 3C).Several cathepsins were undetectable in either cell type,
including the placental cathepsins J, R, 3, 6, and 8, as well as
cathepsins 7 and G. When nontreated ESCs were compared to
ESCs treated with ETO and allowed to recover, no discernible
patternwas apparent. ThemRNA levels for cathepsins E, F, K, L,
O, and Q, however, increased in the ESCs treated with ETO,
suggesting that in addition to cathepsins B, L, S, and H, many
other cathepsins may variably participate in ETO-induced PCD.
To investigate the activation status of several cathepsins
following ETO treatment in ESCs, western blots were conducted
using commercially available antibodies. Fig. 3D shows that
cathepsins B, L, H, and D are all activated following ETO
exposure, albeit at different levels, indicating that these
cathepsins participate in ETO-induced PCD.
Figure 3 Role of lysosomal proteases in ETO PCD. A. ESCs were treated with ETO or left nontreated and coincubated with zFA to
inhibit lysosomal proteases B, L, S, and H, PD150606 to inhibit calpains 1 and 2, or a cathepsin G inhibitor and subjected to flow
cytometry to measure loss of plasma membrane integrity. A minimum of 6 experiments are displayed. Error bars represent the SEM. B.
ESCs were treated with zFF and cotreated with ETO as indicated. Flow cytometry measuring violet cell stain is displayed. C. RT-PCR of
murine cathepsins. RNA was isolated from nontreated MEFs, ESCs, as well as ESCs treated with ETO and harvested at the 4/24 and 4/
48 time points. Complimentary DNA was generated and PCR was performed using primers designed against murine cathepsins. Gapdh
served as a loading control. D. ESCs were treated as indicated and whole cell extracts were used for western blots. Levels of inactive
(pro) and active cathepsins are displayed. Actin served as a loading control. *pb0.05 and #pb0.01.
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The p53 protein has been implicated in ETO-induced PCD in
hESCs (Grandela et al., 2007) and other cell types (Arriola et
al., 1999; Karpinich et al., 2002), and can play a role in the
disruption of the lysosomal membrane, which subsequently
results in cathepsin release during PCD (Johansson et al.,
2010; Li et al., 2007; Yuan et al., 2002). InmESCs, p53 is stable
and predominantly cytoplasmic (Bialik and Kimchi, 2004;
Edinger and Thompson, 2004; Findeisen et al., 2004), an
observation we confirmed (Fig. 4A). When challenged with
ETO, a large portion of p53 was translocated to the nucleus,
while a fraction remained extranuclear. Phosphorylation ofp53 ser-18 (p53 ser-15 in humans) by ATM is a signature of p53
stabilization and activation (Ashcroft et al., 2000; Nakagawa
et al., 1999). Western blots of mESC lysates showed that
phosphorylated p53 substantially increased after ETO treat-
ment, while the total level of p53 remained stable (Fig. 4B).
The level of p53 protein is regulated in multiple ways. As
previously indicated, Spautin 1 inhibits proteases USP10 and
USP13, which results in the stabilization of Beclin 1. USP10
also has been implicated in regulating the abundance and
function of p53 (Reece and Figg, 2010). Since Beclin 1 does not
appear to be involved in ETO-induced cell death in mESCs
(Fig. 3C), we considered the possibility that p53, the other
known target of Spautin 1, might contribute to ETO-mediated
Figure 4 P53 promotes ETO-induced PCD. A. ESCs were treated with ETO or left nontreated and fixed and stained with p53
antibody. B. Western blot using ESC whole cell lysates that were treated with ETO or left nontreated and harvested at the indicated
time points and probed with the indicated antibodies. Actin served as a loading control. C. Western blots displaying the levels of p53
and Beclin 1 proteins in ESCs treated with ETO or left nontreated and incubated with Spautin 1. D. Quantitation of protein levels in C
using ImageJ software. Band intensities were normalized to respective actin controls. E. Flow cytometric death analysis of ESCs
treated with ETO or left nontreated and incubated with either pifithrin α to prevent transactivation of p53 target genes or pifithrin μ
to prevent any mitochondrial function of p53. F. Flow cytometric death analysis of p53 proficient (+/+) ESCs (WD44) or p53 deficient
(−/−) ESCs.*pb0.05 and #pb0.01.
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435ETO-induced PCD pathways in mouse ESCscell death. Treating mESCs with Spautin 1 reduced the level of
p53 protein following ETO administration compared to cells
treated with ETO alone, but only at the 4/24 time point
(Figs. 4C and D). A slight reduction in Beclin 1 was also seen in
the ETO 4/48 time point when cells were cotreated with
Spautin 1 (Fig. 4C). However, levels of p53 were not
significantly reduced in cells concomitantly with ETO and
Spautin 1 at the 4/48 time point. The data suggest that Spautin
1 inhibits cell death through a novel mechanism, since
knockdown of Beclin 1 had little effect on cell death levels
following ETO treatment (Fig. 2C) and p53 levels are not
dramatically reduced in ETO and Spautin 1 treated cells at the
4/48 time point (Fig. 4D). Spautin 1 also appears to induce a
cellular stress response, as evidenced by an increase in the
level of p53 phospho-ser 18 levels in the cells jointly treated
with ETO and Spautin 1 compared to control cells treated only
with ETO (Fig. 4C).
In many cell types, phosphorylation of ser18 on p53 results
in p53 stabilization and its translocation to the nucleus, where
it can induce the expression of target genes involved in cell
cycle arrest and apoptosis. To address whether p53 plays a
role in ETO-induced PCD in mESCs, the levels of cell death
were quantified after treatment with ETO alone or together
with pifithrin α to prevent the transactivation of p53. Since
p53, in addition to its nuclear functions, can also play a role in
PCD by translocating to the mitochondria and activating BAX
(Pettersen et al., 2004), mESCs were treated with ETO and
with pifithrin μ to reduce p53 association with mitochondria
before assessment of cell death. Cell death was significantly
reduced in a dose-dependent manner when cells were treated
with either pifithrin α or pifithrin μ in addition to ETO at both
the 4/24 and 4/48 time points (Fig. 4E). Although treatment
with pifithrinμ by itself was slightly cytotoxic, it protected the
cells from ETO-induced cell death. At lower doses (10 μM),
pifithrin μ was not cytotoxic but the overall reduction in
ETO-induced PCD was less pronounced but still statistically
significant (Supplemental Fig. 6). To confirm that p53 plays a
role in ETO-induced PCD, p53−/− and p53+/+ mESCs were
assayed for levels of cell death following ETO exposure.
ETO-induced PCD was significantly lower in the p53-deficient
ESCs at the 4/48 time point compared with a p53 proficient
controls (Fig. 4F), indicating that p53 is a significant
participant in ETO-induced PCD in mESCs.ETO-induced DNA fragmentation
When mESCs are treated with ETO, DNA is cleaved into
fragments of defined size, a hallmark of PCD. Fragment size
depends on the nuclease activated in the death signaling
cascade. Although CAD cleaves cellular DNA into nucleosomal-
sized fragments inmany cell types, it is unlikely to be themain
culprit enzyme in mESC-induced PCD since caspases do not
appear to be significantly activated in mESCs following ETO
exposure and since caspase inhibition does not result in a
reduction in cell death. Nevertheless, to test the involvement
of CAD on DNA fragmentation in mESCs, the intracellular
localization of CADwas determined before and after challenge
with ETO. Prior to challenge, CAD was localized almost
exclusively within the nucleus and remained there after
treatment (Fig. 5A). This is noteworthy since in some cell
types, CAD resides in the cytoplasm and translocates to thenucleus upon death (Liu et al., 1997). In other cell types CAD
remains in the nucleus prior to and following DNA damaging
treatments (Samejima and Earnshaw, 1998). The inhibitor of
CAD, ICAD, which exists as two splice variants designated
ICADL and ICADS, regulates CAD activity. Caspases are among
the main proteases that cleave and inactivate ICAD, but they
are not alone in this activity. After treatment of mESCs with
ETO and subsequent recovery, there was some ICAD degrada-
tion, particularly the ICADL isoform, suggesting that CAD could
be involved in the observed DNA fragmentation (Fig. 5B). The
ancillary degradation of ICAD protein during late stage cell
death by nonspecific proteases, however, cannot be excluded.
Two other enzymes that may contribute to ETO-induced
DNA fragmentation in mESCs are AIF and EndoG, both of
which have the capacity to fragment DNA during PCD after
translocating from the mitochondria to the nucleus. When
mESCs were treated with ETO and allowed to recover, AIF
remained extranuclear (Fig. 5C), indicating that it does not
play a role in ETO-induced DNA fragmentation. EndoG, like
AIF, localizes to the mitochondria, and can relocate to the
nucleus and induce nucleosomal-sized DNA fragmentation,
particularly under conditions of oxidative stress (Ishihara
and Shimamoto, 2006). During ETO-induced PCD, much of
the EndoG was found in the cytosol prior to treatment and in
the nucleus after ETO treatment, suggesting that it may
participate in ETO-induced DNA fragmentation (Fig. 5D).
When siRNAs to EndoG were used, the level of EndoG protein
was reduced (Fig. 5E), as was the level of DNA fragmentation
in both attached and floating cells (Fig. 5F), indicative of
EndoG involvement in PCD. When cell death levels were
measured in ESCs transfected with EndoG or control siRNAs
and then treated with ETO, a significant reduction in cell
death was observed, confirming a role for EndoG in ETO-
induced PCD in mESCs (Fig. 5G).Discussion
Although ETO induces PCD in several cell types (Fujino et al.,
2002; Mayorga et al., 2004; Mizumoto et al., 1994; Tsujimoto,
1997; Yoo et al., 2012), the pathway(s) involved is not
completely understood. We now show that ETO induces a
PCD pathway in mESCs, which we now coin charontosis, that
appears independent of caspase activity. Although there is a
single report which argues that exposure to ETO induces
caspase 3 activation (Grandela et al., 2007), it is based on
hESCs, which may differ in behavior from mESCs. A separate
account supports our findings that caspase 3 is not activated in
mESCs (Mantel et al., 2007), arguing that cells of the same
type but of different species originmay differ in their response
to ETO exposure. In addition to their roles in apoptosis, the
activity of caspases, particularly that of caspase 3, have been
implicated in retinoic acid-induced differentiation of hESCs,
and in the differentiation of both murine-derived myoblasts
and neural stem cells (Fernando et al., 2005; Fujita et al.,
2008; Larsen et al., 2010). Similarly, nucleoside analogs can
trigger caspase-7-dependent cleavage of Oct4 to induce
differentiation of embryonic carcinoma cells, which have
many similarities to ESCs, suggesting that caspase activity is
important during the differentiation process (Musch et al.,
2010). We observe caspase 3 cleavage during retinoic
acid-induced mESC differentiation (Supplemental Fig. 7),
Figure 5 DNA fragmentation in ETO-induced PCD. A. ESCs were treated as indicated, fixed, and stained with antibody to
caspase-activated DNase (CAD). Nuclei were stained with Draq5. B. Western blot on ESCs treated as indicated and probed for antibody
to ICAD or actin. C. ESCs were treated as indicated and probed with antibody to apoptosis-inducing factor (AIF). Draq5 was used to
stain nuclei. D. Immunofluorescent staining of EndoG in ESCs treated as indicated. Note that a large portion of EndoG translocates
into the nucleus after treatment. E. Western blot showing the level of knockdown of EndoG using two different siRNAs in ESCs after
treatment with ETO and harvested at the 4/48 time point. Protein lysates were generated from remaining attached cells. GFP was
used to show level of transfection between the transfected cells. F. DNA fragmentation assay on DNA isolated from 4/48 ETO-treated
cells, either floating or attached after transfection with control or EndoG siRNAs. G. Flow cytometric analysis of levels of death in
ESCs following transfection of EndoG siRNAs and ETO treatment. *pb0.05 and #pb0.01.
436 E.D. Tichy et al.suggesting that caspase activation is stimulus-specific in
mESCs. Although the data are not sufficient to argue
unequivocally that caspases directly contribute to charontosis
in mESCs, their participation remains a viable possibility.
Survivin and XIAP, members of the inhibitor of apoptosis
protein (IAP) family, can bind to and inhibit caspases, and are
abundant in unchallenged mESCs (Supplemental Fig. 8A).
Survivin is regulated by the Oct4 pluripotency transcription
factor (Guoet al., 2008),whichmay explain why it is expressed
at such high levels and why caspase activity appears inhibited
in mESCs, at least after ETO treatment. Also, both Survivin and
c-IAP2 proteins are induced following ETO treatment in mESCs
(Supplemental Fig. 8B). Thus, the low caspase activity may be
explained in part by the level of IAP expression in mESCs.
After a four hour exposure to ETO and 44 h of recovery,
RIP1 expression was elevated, indicative of necroptosis. This
observation is similar to what is seen in cell lines treated with
ETO, and is consistent with the suggestion that an increase in
RIP1 may contribute to necroptosis in ETO-mediated PCD(Tenev et al., 2011). A functional role for increased RIP1
expression in ETO-induced necroptosis in mESCs, however was
not seen, either by siRNA inhibition of the RIP kinases, or by
necrostatin-1 inhibition of RIP1. Interestingly, necroptosis,
specifically the formation of the ripoptosome, can also be
inhibited by c-IAP1 and c-IAP2 (Feoktistova et al., 2011).
Expression of c-IAP2 was increased following ETO treatment
(Supplemental Fig. 8B), suggesting that elevated IAPs might
impair necroptosis in ESCs treated with ETO.
Autophagy is frequently activated during PCD in many cell
types, irrespective of how cell death is induced (Goehe et al.,
2012; Hughson et al., 2012; Munoz-Gamez et al., 2009; Orlotti
et al., 2012). Exposure of human cervical cancer cells to
therapeutics such as ETO promotes autophagy, while inhibition
of autophagy by 3-methyladenine reduces PCD (Lee et al.,
2007). Similarly, ETO treatment of Bax/Bak-deficient MEFs
induces cell death with autophagic features (Shimizu et al.,
2004). Conflicting evidence, however, suggests that reducing
autophagy in HepG2 cells with siRNA to Beclin 1 or with
437ETO-induced PCD pathways in mouse ESCs3-methyladenine increases ETO-induced cell death (Xie et al.,
2011). Similar results in other cancermodel systems (Amaravadi
et al., 2007; Apel et al., 2008; Guo et al., 2012; Han et al.,
2011), have led to clinical trials in which autophagy is targeted
(Amaravadi et al., 2011). Whether autophagy is a direct
activator of cell death or a passive bystander activated during
the process of PCD remains controversial. There are conflicting
data from different cell models and a lack of specific phar-
macological inhibitors of autophagy (Kroemer and Levine, 2008;
Levine and Yuan, 2005). The resolution to this issue may not be
simple, since autophagy may be a prerequisite to some PCD
pathways (Chen et al., 2011), and inhibition of autophagy may
induce compensatory pathways of PCD activation. The timing at
which autophagy is inhibited and the impact that this timing
may have on PCD is yet another confounding factor. Inhibition of
early signalingwithin the autophagy pathway after treatment of
glioma cells with imatinib promotes cell survival, while the
inhibition of autophagy at a later stage results in loss of the
protective effect and increased cell death (Shingu et al., 2009).
Inhibition of autophagy in mESCs at several different stages of
the autophagic process using siRNAs revealed no significant
reduction of PCD following ETO exposure. In fact, knockdown of
the autophagy mediators Atg5 or Beclin 1 tended to produce a
higher level of cell death. Although treatment of mESCs
with BA1, an inhibitor of late stage autophagy, significantly
reduced PCD, an unequivocal role for autophagy in PCD was
not established. Indeed, the data indicated that autophagy in
mESCs has a pro-survival function in mESCs after ETO
treatment. This finding suggested that other pathways,
including those involving the lysosome, might be active in
mESC PCD.
Because cathepsins are located within lysosomes and can
be targeted by BA1, and because they participate in many cell
death pathways, they are attractive candidates as effectors of
charontosis in mESCs (Broker et al., 2004; Droga-Mazovec et
al., 2008; Hsu et al., 2009; Kagedal et al., 2001; Zuzarte-Luis
et al., 2007). We have shown that a broad spectrum cathepsin
inhibitor, which targets cathepsins B, L, S, and H, produces a
significant reduction or delay in ETO-induced PCD. These
specific cathepsins, however, do not contribute to Parp-1
cleavage (Supplemental Fig. 9). Although many other
cathepsins were elevated after treatment with ETO at the
RNA level, their functional involvement in Parp-1 cleavage and
charontosis is only inferential. Since cathepsins exist as
zymogens that are not fully active until they are cleaved,
RNA expression data cannot be considered sufficient to assign
functional activity. Thus, the cathepsin(s) responsible for
Parp-1 cleavage, and other cathepsins that promote
charontosis has not yet been identified.
Cathepsins other than B, L, S, and H can also be involved
in PCD signaling. For example, the involvement of cathepsin
D in PCD has been described in response to a variety of
stimuli (Johnson, 2000). Cathepsin D is also released from
lysosomes into the cytosol in U937 lymphoma cells and HeLa
cells in response to several DNA damaging agents, including
ETO (Emert-Sedlak et al., 2005). Furthermore, siRNAs that
target cathepsin D in these cells can partially alleviate PCD
(Emert-Sedlak et al., 2005). We have also observed
cathepsin D activation following ETO exposure in mESCs
(Fig. 3D), however, the lack of a specific pharmacological
inhibitor to cathepsin D has made assaying its role in ETO-
induced PCD difficult. In MEFs deficient for Bak and Bax,cathepsin Q plays a role in ETO-induced PCD signaling that
requires p53 transcriptional activity (Tu et al., 2009). Thus,
the possibility that additional cathepsins collaborate in
ETO-induced charontosis remains a viable one, especially
since the protective effect that zFA exerts on ETO-treated
mESCs is not sufficient to completely alleviate the high level
of PCD.
In hESCs, p53 transactivation of target genes is important
for ETO-induced PCD (Grandela et al., 2007). Inhibition of p53
by pifithrin μ also significantly reduced levels of cell death in
these cells. Consistent with these data, we show that pifithrin
μ protects mESCs from cell death, suggesting that p53 plays a
role inmitochondrial-dependent PCD. Additionally, treatment
of mESCs with pifithrin α was also protective against ETO-
induced PCD, although not to the same extent as pifithrin μ.
The ability of pifithrin α to prevent p53 transactivation is
somewhat controversial, particularly at doses greater than
30 μM (Walton et al., 2005). However, several other studies
show that pifithrin α does indeed prevent the expression of
p53 target genes, particularly at doses of 30 μM or lower
(Bragado et al., 2007; Jiang et al., 2006; Menendez et al.,
2011; Schneider-Stock et al., 2005). At a high dose (30 μM),
pifithrin α had no effect on ETO-induced PCD levels (Supple-
mental Fig. 6). At lower doses, mESCs displayed slight but
statistically significant reductions in ETO-induced PCD, indi-
cating that p53 transactivation is partially responsible for
ETO-induced PCD (Fig. 4D). A comparison of ETO-induced
death levels in p53+/+ and p53−/− mESCs has shown that p53 is
unequivocally involved in charontosis. However, since com-
plete protection from death was not observed in p53−/− cells,
then p53-independent pathways must also be involved. We
cannot rule out the contribution of the p53 family members
p63 and p73, particularly since data describing the functions
of these proteins in mESCs are severely lacking. Both of these
proteins have been reported to induce apoptosis in a variety of
cell types, dependent and independent of p53 activity in PCD
signaling (Alonso et al., 2009; Codelia et al., 2010; Dohn et al.,
2001; Flores et al., 2002; Melino et al., 2004; Petre-Lazar et
al., 2007; Pyati et al., 2011; Rana et al., 2010).
DNA fragmentation is an essential component of PCD. Of
several nucleases that were tested for their involvement in
charontosis, EndoG emerged as a likely candidate, although a
role for CAD cannot be discounted due to the degradation of
ICAD observed 44 h after ETO treatment. EndoG is activated in
cells undergoing oxidative stress and translocates to the
nucleus to fragment DNA (Higgins et al., 2009; Ishihara and
Shimamoto, 2006). ETO induces oxidative stress and reactive
oxygen species (ROS) in a variety of cell types (England et al.,
2004; Hirano et al., 2004; Rojas et al., 2009), an observation
we have observed in mESCs after ETO treatment (Supplemen-
tal Fig. 10), adding credence to the involvement of EndoG
in this process. Finally, since pifithrin μ inhibits p53 associa-
tion with mitochondria and results in decreased PCD in
ETO-treated mESCs, and since EndoG is released from
mitochondria to promote DNA fragmentation in response to
ETO treatment, p53 may contribute to EndoG release.
In summary, we have shown that ETO induces massive
DNA DSBs, an accumulation of cells in the G2 phase of the
cell cycle, and extensive PCD in mESCs (Fig. 1; Supplemental
Fig. 11). This PCD appears to be independent of caspase
activity and of RIP kinases, which are active in necroptosis.
Knockdown of proteins that are integral to autophagy did not
Figure 6 Model of ETO-induced PCD (charontosis) in mESCs.
Etoposide promotes p53 translocation from the cytoplasm to the
nucleus to promote transcription of target genes involved in cell
death. This activity is reduced following treatment with
pifithrin α (PFα). A portion of p53 remains outside the nucleus
and presumably translocates to mitochondria to inactivate
pro-survival Bcl-2 family members. Pifithrin μ (PFμ) can reduce
p53 association with mitochondria, resulting in protection from
death. The mitochondria may release ROS, which can disrupt
the lysosomal membrane and cause release of cathepsins, which
cleave specific target proteins. P53 may also translocate to the
lysosome and result in the release of cathepsins. The activities
of several cathepsins are inhibited by zFA and zFF, which reduce
ETO-induced PCD. Bafilomycin A1 (BA1) inhibits lysosomal
acidification, resulting in decreased cathepsin activity and
reduced PCD. Spautin1 can inhibit ubiquitin-specific proteases
that can regulate p53, although other targets are known to
exist. Finally, EndoG is released from mitochondria to induce
DNA fragmentation.
438 E.D. Tichy et al.reduce PCD, whereas chemical inhibitors of autophagy did
significantly decrease the high levels of cell death after
treatment with ETO. The possibility that autophagy itself
promotes PCD was excluded, since the activation of
autophagy during ETO treatment promoted cell survival
and not cell death. When mESCs were exposed to a broad
spectrum inhibitor of cathepsins, the level of cell death was
significantly reduced suggesting that these lysosomal pro-
teases were involved in PCD. The involvement of p53 was
also queried by the use of inhibitors that prevent p53
transactivation or mitochondrial translocation. Inhibitors of
both p53 activities significantly protected ESCs from ETO-
induced PCD, albeit at varying degrees. Lastly, we have
identified a novel role for EndoG in the ETO-induced PCD
pathway in mESCs, a finding that has not been described in
ETO-induced PCD in any other cell type. We have coined the
term charontosis, after Charon, the ferryman on the river
Styx in Greek mythology, to describe this PCD pathway,
which is summarized in Fig. 6.
Supplementary data to this article can be found online at
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